Tempus

What is Tempus?

Tempus AI is a precision medicine platform that uses artificial intelligence to transform healthcare by integrating clinical records, genomics, imaging, and real-world data. Founded in 2015 by Eric Lefkofsky in Chicago, the company builds AI-driven diagnostic and decision-support tools primarily for oncology, while also serving cardiology, radiology, neuropsychiatry, and depression. Tempus operates one of the world's largest libraries of multimodal clinical and molecular data, enabling physicians to make real-time, data-driven decisions for personalized patient care.

The platform offers comprehensive genomic profiling through tissue NGS panels and ctDNA/xM liquid biopsy assays for tumor characterization, minimal residual disease monitoring, and therapy selection. Tempus OS serves as a modular operating system that lets providers query multimodal data, run AI algorithms, and integrate seamlessly with electronic medical records. Key capabilities include AI-enabled clinical decision support that flags care gaps and recommends guideline-matched therapies, automated clinical trial matching through the TIME program, and longitudinal biomarker tracking.

Tempus is designed for oncologists, healthcare providers, health systems, biopharma companies, and researchers. Physicians use it to order diagnostic tests, view actionable patient reports, and identify clinical trial matches at the point of care. Biopharma partners leverage Tempus for trial enrollment, biomarker discovery, and data licensing. The company goes public on Nasdaq under ticker TEM in June 2024 and employs approximately 2,300-3,800 people.

The platform supports multiple disease areas beyond cancer, including pharmacogenomic testing for psychiatric conditions like depression and anxiety, cardiac MR image analysis through Tempus Pixel, and radiology applications. Its intelligent diagnostics use generative AI to make laboratory tests more accurate, tailored, and personal, while the Next platform delivers real-time patient insights across clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers.

Tempus pricing

Pricing model: Free

Tempus does not offer a free tier. Clinical Testing (Oncology Diagnostics): Genomic and liquid biopsy tests including tissue NGS panels and ctDNA/xM assays are billed at $1,500-$3,000 USD per test before insurance. Actual out-of-pocket patient costs depend on insurance coverage, financial assistance, and institutional arrangements. Biopharma & Trial Solutions: Partners pay per-test fees ($1,500-$3,000 per patient for specialized assays) plus trial enrollment and activation fees ($50,000-$200,000 per trial). Data licensing from de-identified clinical and molecular datasets generates hundreds of millions annually. Platform & Data Partnerships: Health systems and researchers license access to Tempus' 25+ million clinical records and platform tools via bespoke enterprise contracts with pricing based on scale, data access level, and integration depth. No publicly disclosed subscription plans exist—pricing is project-based and negotiated.

Tempus pros

• Massive multimodal data library with 25+ million clinical records enabling powerful AI models
• Comprehensive genomic profiling covering DNA, RNA, somatic and germline mutations in one assay
• Integrated platform combining testing, AI decision support, EMR integration, and research data
• AI-powered clinical trial matching identifies 25% more eligible patients than traditional methods
• Clinical trial activation up to 3x faster through just-in-time site activation
• FDA-cleared AI tools including ECG-AF for cardiology and histogenomics for pathology
• Real-time care pathway analysis detects deviations from clinical guidelines at point of care
• Minimal residual disease monitoring through Tempest XM portfolio for cancer surveillance
• No-code workflow automation and AI runtime in Tempus OS for custom agent building
• Seamless integration with major electronic health record systems
• Longitudinal biomarker tracking enables monitoring of disease progression over time
• Strong partnerships with AstraZeneca, Illumina, SoftBank, and leading health systems
• CAP/CLIA-certified next-generation sequencing laboratory ensuring quality standards
• Expanded disease coverage beyond oncology to cardiology, radiology, and psychiatry
• De-identified data licensing for academic and biopharma research in secure environments
• Pharmacogenomic testing for psychiatric conditions including depression and bipolar disorder
• Tempus Pixel provides automated cardiac MR image reporting improving efficiency

Tempus cons

• Enterprise and lab-centric pricing makes it primarily suitable for large health systems
• Genomic tests cost $1,500-$3,000 per test before insurance, limiting accessibility
• Complex EMR integration requires significant IT resources and change management
• Heavy regulatory and data governance compliance overhead for genomics and AI
• Steep learning curve for users unfamiliar with genomics or bioinformatics
• Requires substantial computational resources for large-scale data processing
• Data privacy concerns from managing large volumes of sensitive patient health information
• Initial development focused on oncology may limit immediate applicability to other diseases
• High licensing costs may be prohibitive for smaller clinics and institutions
• Limited availability of trained personnel proficient in advanced biomedical AI tools

Categories

• Education & Research

Use cases

• Code Assistant
• Data Analysis